Wound Management News

Castle Creek Pharmaceuticals announced it has enrolled the first patient in its phase 2/3 clinical trial to measure safety and efficacy of CCP-020, diacerein 1% ointment, for treating epidermolysis bullosa simplex.

NEW ORLEANS — Taksta was noninferior to Zyvox as an oral treatment for acute bacterial skin and skin structure infections, or ABSSSIs, including MRSA, according to phase 3 data presented here.

NEW ORLEANS — Data from two phase 3 trials demonstrated that IV and oral Baxdela had similar safety and efficacy profiles against acute bacterial skin and skin structure infections, or ABSSSIs, compared with a combination regimen of vancomycin and aztreonam among patients with a history of infectious hepatitis.

Researchers found that the microbiome in hidradenitis suppurativa lesional and nonlesional skin differed significantly from the skin of healthy controls, suggesting a link between dysbiotic cutaneous microbiome and the skin disease, according to recently published study results in JAMA Dermatology.

Survey findings that less than half of women assisted their husbands with skin self-examinations was among the top read articles in May on Healio.com/Dermatology.

Patients with non-small cell lung cancer treated with epidermal growth factor receptor inhibitors rarely experienced purpuric skin lesions, which had characteristic clinical and histopathologic presentations, according to study results recently published in JAMA Dermatology.

Researchers identified early signs and risk factors of methotrexate-induced epidermal necrosis, and physicians should use caution when deciding when to prescribe methotrexate to high-risk patients, according to recently published study results in the Journal of the American Academy of Dermatology.

A large percentage of surveyed dermatology residents reported facial splash by blood or other potentially infectious material during a procedure while not wearing facial protection, according to research published in Dermatologic Surgery.

BERG, a clinical-stage biopharmaceutical company, announced it has partnered with The Dystrophic Epidermolysis Bullosa Research Association of America to support and advocate for patients and families effected by epidermolysis bullosa.

Treatment of skin infections with the antibiotic omadacycline was noninferior to Zyvox in a phase 3 study, researchers said at the European Congress of Clinical Microbiology and Infectious Diseases in Vienna.